Loading
Diabetes Management and Research / Diabetes Treatment and Management · Review
The Indonesian Journal of General Medicine · August 7, 2026
Well-designed and adequately powered for the question it asks.
This systematic review of 32 RCTs comprising nearly 30,000 participants demonstrates that GLP-1 receptor agonists produce consistent and clinically significant reductions in HbA1c (−0.5% to −1.75%) and body weight across diverse patient backgrounds and comparators, with additional benefits in cardiovascular and renal outcomes. The breadth of evidence, consistency of effect direction and magnitude, low risk of bias in the majority of included trials, and dose-response relationship establish GLP-1 RAs as a robustly effective class for glycaemic control and weight reduction in type 2 diabetes.
Systematic review of randomized controlled trials. Adults with type 2 diabetes mellitus from 32 randomized controlled trials comparing GLP-1 receptor agonists with placebo or active comparators (metformin, sulphonylurea, SGLT-2 inhibitor, basal insulin, exenatide, dulaglutide). Intervention: Glucagon-like peptide-1 receptor agonists (including subcutaneous semaglutide, once-weekly semaglutide 7.2 mg, exenatide extended release, dulaglutide) as monotherapy or in combination with metformin, sulphonylurea, SGLT-2 inhibitor, or ba…. Compared with: Placebo or active comparators (exenatide extended release, dulaglutide, or standard background regimens). n = 29,958.
Every placebo-controlled comparison showed statistically and clinically significant HbA1c reduction, with treatment differences ranging from −0.5% to −1.75% (all p<0.001) Subcutaneous semaglutide produced HbA1c reduction up to −1.53% and weight loss up to −5.06 kg versus placebo, superior to exenatide extended release (−0.62% HbA1c; −3.78 kg) and dulaglutide (−0.41% HbA1c; −3.55 kg) Once-weekly semaglutide 7.2 mg reduced body weight by 13.2% (ETD −9.3%) with HbA1c ETD of −1.5%
Major adverse cardiovascular events (HR 0.88; 95% CI 0.79–0.99) and renal events (HR 0.85; 95% CI 0.77–0.93) reduced in REWIND; systolic blood pressure reduced up to −5.0 mmHg
Clinicians should consider GLP-1 receptor agonists a preferred treatment option for patients with type 2 diabetes who have concomitant overweight or obesity and elevated cardiovascular risk, given consistent and clinically significant improvements in glycaemic control, weight reduction, and cardiorenal outcomes across diverse patient populations and background regimens. Implementation decisions should account for gastrointestinal tolerability and cost, particularly in resource-constrained health-care settings.
Systematic review of 32 RCTs with 29,958 participants demonstrating consistent, clinically significant HbA1c reduction (−0.5% to −1.75%, all p<0.001) and weight loss across diverse comparators, with low risk of bias in 23 studies and GRADE-assessed certainty.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should consider GLP-1 receptor agonists a preferred treatment option for patients with type 2 diabetes who have concomitant overweight or obesity and elevated cardiovascular risk, given consistent and clinically significant improvements in glycaemic control, weight reduction, and cardiorenal outcomes across diverse patient populations and background regimens. Implementation decisions should account for gastrointestinal tolerability and cost, particularly in resource-constrained health-care settings.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction: Type 2 diabetes mellitus (T2DM) is a metabolic disorder with a rapidly escalating global burden and is closely linked to obesity and cardiovascular disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an incretin-based therapeutic class that simultaneously targets hyperglycaemia and adiposity. This systematic review aimed to evaluate the efficacy of GLP-1 RAs on glycaemic control and weight reduction in T2DM on the basis of randomized controlled trial (RCT) evidence. Methods: The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible studies were RCTs in adults with T2DM comparing a GLP-1 RA with placebo or an active comparator and reporting HbA1c and/or body weight outcomes. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool and certainty of evidence using the GRADE approach. Because of substantial clinical heterogeneity, evidence was synthesised in a structured narrative format rather than pooled quantitatively. Results: Thirty-two RCTs comprising 29,958 participants met the eligibility criteria. Every placebo-controlled comparison demonstrated a statistically and clinically significant reduction in HbA1c, with estimated treatment differences (ETDs) ranging from -0.5% to -1.75% (all p<0.001). Subcutaneous semaglutide produced HbA1c ETDs of up to -1.53% and weight reductions of up to -5.06 kg versus placebo, and was superior to exenatide extended release (ETD -0.62%; -3.78 kg) and to dulaglutide (ETD -0.41%; -3.55 kg). Once-weekly semaglutide 7.2 mg reduced body weight by 13.2% (ETD -9.3%) with an HbA1c ETD of -1.5%. The proportion achieving >=5% weight loss reached 68.8% in STEP 2 (odds ratio 4.88) and yielded an odds ratio of 10.0 in STEP UP T2D. Benefit was consistent across 16 outcome domains, including fasting plasma glucose, waist circumference, systolic blood pressure (ETD up to -5.0 mmHg), insulin requirement (glargine titration difference -13 U/day), and major adverse cardiovascular (HR 0.88; 95% CI 0.79-0.99) and renal (HR 0.85; 95% CI 0.77-0.93) outcomes in REWIND. Hypoglycaemia risk remained low, whereas mild-to-moderate gastrointestinal events were the most frequent adverse events. Twenty-three studies were judged at low risk of bias and nine raised some concerns, chiefly owing to open-label designs. Discussion: The consistency of the direction and magnitude of effect across 32 RCTs spanning diverse background regimens (monotherapy, metformin, sulphonylurea, SGLT-2 inhibitor and basal insulin combinations) supports a robust and reproducible class effect. A clear dose-response relationship, the superiority of semaglutide in head-to-head comparisons, and the accompanying cardiorenal benefit reinforce the position of this class within T2DM treatment algorithms for patients with concomitant obesity. Gastrointestinal tolerability and cost remain the principal implementation considerations, particularly within the Indonesian health-care setting. Conclusion: GLP-1 receptor agonists consistently and significantly improve glycaemic control and reduce body weight in T2DM, with a low risk of hypoglycaemia and additional cardiorenal benefit in high-risk populations. The evidence supports positioning GLP-1 RAs as a preferred option in patients with T2DM and overweight or obesity and elevated cardiovascular risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.